Correction: Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma,Egyptian Liver Journal

当前位置： X-MOL 学术 › Egypt. Liver J. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Correction: Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma
Egyptian Liver Journal Pub Date : 2023-12-18 , DOI: 10.1186/s43066-023-00302-7
Mohamed Houseni , Mahmoud Abdel Aziz Abdel Hady , Sameh Abokoura

Correction: Egypt Liver Journal 13, 41 (2023)

https://doi.org/10.1186/s43066-023-00276-6

Following publication of the original article [1], the abstract and keywords were missing from this article and should have read:

Abstract

Objective: This study’s purpose was to evaluate the response, safety and overall survival of trans-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with preserved hepatic function.

Methods: This study was carried out on 25 patients, diagnosed with hepatocellular carcinoma (HCC) combined with portal vein tumor thrombosis (PVTT) and underwent hepatic artery infusion chemotherapy (HAIC). Radiological investigations as Triphasic CT or dynamic MRI liver assessment pre and post therapy were acquired. Intra-Arterial chemotherapeutic agent infusion using only doxorubicin was performed.

Results: Neither of the patients who underwent HAIC developed complete or partial response. Only one patient (4.8%) from 21 patients under HAIC had stable disease. 20 patients (95%) had progressive disease. Progressive disease was in form of progression at the primary tumor site in form of increased focal lesion size, number or vascular invasion. Vascular invasion was seen in one patient (4.8%) in the form of hepatic vein thrombosis. Mean progression free survival was about 2.24 ± 0.88 months. Mean overall survival was about 5.72 ± 0.89 months.

Conclusion: Our study demonstrated lower clinical efficacy and lower disease control rate of repeated HAIC using doxorubicin only infusion in case of advanced HCC with PVT as compared to combined doxorubicin and cisplatin in previous studies as well as the standard therapy with sorafenib.

Keywords

Hepatic artery infusion chemotherapy, Portal vein tumor thrombosis, Advanced hepatocellular carcinoma

The original article [1] has been updated.

Houseni M, Hady MAAA, Abokoura S (2023) Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. Egypt Liver J 13:41. https://doi.org/10.1186/s43066-023-00276-6
Article Google Scholar

Download references

Authors and Affiliations

Department of Radiology, National Liver Institute, Menoufia University, Shebin Elkoum, Egypt
Mohamed Houseni, Mahmoud Abdel Aziz Abdel Hady & Sameh Abokoura

Authors

Mohamed HouseniView author publications
You can also search for this author in PubMed Google Scholar
Mahmoud Abdel Aziz Abdel HadyView author publications
You can also search for this author in PubMed Google Scholar
Sameh AbokouraView author publications
You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sameh Abokoura.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and Permissions

Cite this article

Houseni, M., Hady, M.A.A.A. & Abokoura, S. Correction: Hepatic artery infusion chemotherapy for advanced hepatocellular carcinoma. Egypt Liver Journal 13, 70 (2023). https://doi.org/10.1186/s43066-023-00302-7

Download citation

Published: 18 December 2023
DOI: https://doi.org/10.1186/s43066-023-00302-7

Share this article

Anyone you share the following link with will be able to read this content:

Sorry, a shareable link is not currently available for this article.

Provided by the Springer Nature SharedIt content-sharing initiative

中文翻译：

纠正：晚期肝细胞癌的肝动脉灌注化疗

更正：埃及肝脏杂志 13, 41 (2023)

https://doi.org/10.1186/s43066-023-00276-6

原文章 [1] 发表后，本文缺少摘要和关键词，应为：

抽象的

目的：本研究旨在评估肝功能保留的晚期肝细胞癌患者经动脉灌注化疗的疗效、安全性和总生存期。

方法：本研究对25例诊断为肝细胞癌（HCC）合并门静脉肿瘤血栓（PVTT）并接受肝动脉灌注化疗（HAIC）的患者进行研究。治疗前和治疗后进行了三相 CT 或动态 MRI 肝脏评估等放射学检查。仅使用阿霉素进行动脉内化疗药物输注。

结果：接受 HAIC 的患者均未出现完全或部分缓解。 HAIC 下的 21 名患者中，只有 1 名患者（4.8%）病情稳定。 20 名患者 (95%) 病情进展。进展性疾病是指原发肿瘤部位的进展，表现为病灶大小、数量或血管侵犯增加的形式。一名患者 (4.8%) 发现血管侵犯，表现为肝静脉血栓形成。平均无进展生存期约为 2.24±0.88 个月。平均总生存期约为 5.72±0.89 个月。

结论：我们的研究表明，与既往联合阿霉素和顺铂治疗晚期 HCC 合并 PVT 的情况相比，仅使用阿霉素重复输注 HAIC 的临床疗效和疾病控制率较低研究以及索拉非尼的标准疗法。

关键词

肝动脉灌注化疗、门静脉肿瘤血栓、晚期肝细胞癌

原文章[1]已更新。

Houseni M、Hady MAAA、Abokoura S (2023) 肝动脉灌注化疗治疗晚期肝细胞癌。埃及肝脏杂志 13:41。 https://doi.org/10.1186/s43066-023-00276-6
文章谷歌学术

下载参考资料

作者和单位

放射科，国家肝脏研究所，梅努菲亚大学，Shebin Elkoum，埃及
穆罕默德·豪斯尼 (Mohamed Houseni)、马哈茂德·阿卜杜勒·阿齐兹·阿卜杜勒·哈迪 (Mahmoud Abdel Aziz Abdel Hady) 和萨米赫·阿博库拉

作者

Mohamed Houseni查看作者出版物
您还可以在PubMed Google Scholar中搜索该作者
Mahmoud Abdel Aziz Abdel Hady查看作者出版物
您还可以在PubMed Google Scholar中搜索该作者
Sameh Abokoura查看作者出版物
您还可以在PubMed Google Scholar中搜索该作者

通讯作者

通讯作者：Sameh Abokoura。

开放获取本文已获得 Creative Commons Attribution 4.0 International License 的许可，该许可允许以任何媒介或格式使用、共享、改编、分发和复制，只要您同意适当注明原作者和来源，提供知识共享许可的链接，并注明是否进行了更改。本文中的图像或其他第三方材料包含在文章的知识共享许可中，除非材料的信用额度中另有说明。如果文章的知识共享许可中未包含材料，并且您的预期用途不受法律法规允许或超出了允许的用途，则您需要直接获得版权所有者的许可。要查看此许可证的副本，请访问 http://creativecommons.org/licenses/by/4.0/。

转载和许可